Chimerix (NASDAQ:CMRX) Given Buy Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Chimerix (NASDAQ:CMRX) in a research note released on Monday morning,Benzinga reports. The firm currently has a $11.00 target price on the biopharmaceutical company’s stock.

Separately, Wedbush reaffirmed an “outperform” rating and set a $6.00 price target on shares of Chimerix in a report on Tuesday, December 10th.

Chimerix Stock Up 1.2 %

Shares of NASDAQ CMRX opened at $3.48 on Monday. The company has a 50 day moving average of $1.66 and a 200 day moving average of $1.16. Chimerix has a twelve month low of $0.75 and a twelve month high of $3.66. The firm has a market cap of $312.98 million, a P/E ratio of -3.70 and a beta of 1.02.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Valeo Financial Advisors LLC grew its position in Chimerix by 566.9% in the 3rd quarter. Valeo Financial Advisors LLC now owns 81,766 shares of the biopharmaceutical company’s stock worth $76,000 after purchasing an additional 69,505 shares during the period. Marshall Wace LLP bought a new position in shares of Chimerix during the 2nd quarter valued at $137,000. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of Chimerix by 66.8% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company’s stock worth $321,000 after buying an additional 138,098 shares during the last quarter. Institutional investors own 45.42% of the company’s stock.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.